- Home
- HQI vs MOLN Comparison
HQI vs MOLN Comparison
Compare HQI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- MOLN
- Stock Information
- Founded
- HQI 2002
- MOLN 2004
- Country
- HQI United States
- MOLN Switzerland
- Employees
- HQI N/A
- MOLN N/A
- Industry
- HQI Professional Services
- MOLN
- Sector
- HQI Consumer Discretionary
- MOLN
- Exchange
- HQI Nasdaq
- MOLN Nasdaq
- Market Cap
- HQI 198.8M
- MOLN 183.2M
- IPO Year
- HQI N/A
- MOLN 2021
- Fundamental
- Price
- HQI $14.67
- MOLN $4.68
- Analyst Decision
- HQI Strong Buy
- MOLN
- Analyst Count
- HQI 2
- MOLN 0
- Target Price
- HQI $18.50
- MOLN N/A
- AVG Volume (30 Days)
- HQI 16.0K
- MOLN 2.1K
- Earning Date
- HQI 03-20-2025
- MOLN 03-13-2025
- Dividend Yield
- HQI 1.64%
- MOLN N/A
- EPS Growth
- HQI N/A
- MOLN N/A
- EPS
- HQI 0.10
- MOLN N/A
- Revenue
- HQI $36,279,000.00
- MOLN $7,105,397.00
- Revenue This Year
- HQI N/A
- MOLN N/A
- Revenue Next Year
- HQI $8.39
- MOLN N/A
- P/E Ratio
- HQI $104.33
- MOLN N/A
- Revenue Growth
- HQI 0.28
- MOLN N/A
- 52 Week Low
- HQI $11.39
- MOLN $3.32
- 52 Week High
- HQI $15.75
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- HQI 60.34
- MOLN 35.14
- Support Level
- HQI $14.02
- MOLN $4.78
- Resistance Level
- HQI $15.71
- MOLN $4.96
- Average True Range (ATR)
- HQI 0.60
- MOLN 0.08
- MACD
- HQI 0.20
- MOLN -0.02
- Stochastic Oscillator
- HQI 66.98
- MOLN 0.00
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.